Yennen's questions to Kezar Life Sciences (KZR) leadership • Q2 2020
Question
Yennen of Wells Fargo inquired about the mechanism of action driving UPCR reduction in the MISSION study, the rationale and implications of the amended trial protocol, the definition of a successful response rate, and details regarding the discontinued MARINA trial's enrollment and screen failures.
Answer
Chief Scientific Officer Christopher Kirk detailed the broad immunomodulatory mechanism, including reductions in autoantibodies and inflammatory gene signatures. Chief Medical Officer Noreen Henig explained the amended MISSION protocol reflects real-world practice, aiming for a broad label, and noted KZR-616's superior profile for chronic use compared to VELCADE. She also confirmed zero patients were enrolled in the MARINA study.